As the risks have been minimised and benefits communicated software-as-a-service (SaaS) has become increasingly accepted at contract research organisations (CRO) and pharmas. Fujitsu is the latest company to enter the sector, launching tsClinical in Japan.
The software supports operations and management, as well as providing a data and services system. Users will be able to tailor the system to their needs, selecting only the relevant services and entering into contracts which finish when the platform is no longer needed.
By making these customisations users can cut their expenditure during clinical trials and in the periods between studies, which is particularly useful for small- to mid-sized companies with one or two products in testing.
Japan-based Fujitsu is offering tests of the system for JPY 150,000 ($1,650) per month, although pricing will vary depending on the services selected.
The user’s workload, and therefore expenditure, is reduced further by the minimisation of internal process validation required for documentation of procedures, facilities and schedules essential for quality control and production.
In addition, use of tsClinical, and other SaaS-based systems, makes it easier for CROs and sponsors located around the world to collaborate. Users access the same IT environment which allows for data sharing and progress management.
Bellsystem24, a Japan-based company providing clinical trial support services, is already using the system. Fujitsu believes the technology and its pricing make the system an attractive option for other CROs and pharmas and is targeting sales of JPY 1bn over the next three years.